MHLW Designates UMN-0501 And Forodesine Hydrochloride Orphan Drugs
This article was originally published in PharmAsia News
Executive Summary
The Drug and Food Board of the Ministry of Health, Labor and Welfare designated UMN Pharma's UMN-0501 and MundiPharma's forodesine hydrochloride orphan drugs during a May 23 session.UMN-0501 is a pandemic influenza vaccine produced by recombinant protein expression. Compared to the current flu vaccines that are produced using eggs, UMN-0501 enables production in larger quantities and shorter time periods. It also has fewer side effects such as allergies, anaphylactic shock and Guilain-Barre syndrome. Forodesine hydrochloride is used to treat relapsing and intractable T-cell lymphoma, and adult T-cell leukemia. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.